{"disease":{"id":"congenital-adrenal-hyperplasia","name":"Congenital adrenal hyperplasia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":10,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"prednisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"synarel","indication_name":"Exclusion of other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"methylprednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"crinecerfont","indication_name":"classic congenital adrenal hyperplasia (CAH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crenessity","generic_name":"CRINECERFONT","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"","drug_class":"Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones."},{"drug_id":"triamcinolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"betamethasone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00250159","title":"Natural History Study of Patients With Excess Androgen","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04890444","title":"China Adrenal Disease Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04463316","title":"GROWing Up With Rare GENEtic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT02795871","title":"Prenatal Dex Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04252001","title":"Growing up With the Young Endocrine Support System (YESS!)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT03760835","title":"Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT02716818","title":"Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Neurocrine UK Limited","has_results":true},{"nct_id":"NCT05162950","title":"Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Region Stockholm","has_results":false},{"nct_id":"NCT04536662","title":"Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04544410","title":"A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":100,"lead_sponsor_name":"Spruce Biosciences","has_results":true},{"nct_id":"NCT04457336","title":"A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":96,"lead_sponsor_name":"Spruce Biosciences","has_results":true},{"nct_id":"NCT03062280","title":"A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Neurocrine UK Limited","has_results":true},{"nct_id":"NCT05299554","title":"Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Neurocrine UK Limited","has_results":false},{"nct_id":"NCT05128942","title":"A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Spruce Biosciences","has_results":true},{"nct_id":"NCT00001521","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":true},{"nct_id":"NCT05101902","title":"A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Adrenas Therapeutics Inc","has_results":false},{"nct_id":"NCT00011791","title":"Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04087148","title":"Linear Growth of Children With Congenital Adrenal Hyperplasia","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06153043","title":"Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05063994","title":"Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Neurocrine UK Limited","has_results":true},{"nct_id":"NCT06756620","title":"Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency","phase":"","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Ozge Bayrak Demirel","has_results":false},{"nct_id":"NCT07099456","title":"Fertility And Sexual Function In CAH: CALLIOPE","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT06449456","title":"Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH","phase":"","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT05669950","title":"A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"H. Lundbeck A/S","has_results":false},{"nct_id":"NCT05907291","title":"Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Crinetics Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04293133","title":"Final Height in Patients With CAH","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT06754423","title":"Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03550261","title":"Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06728748","title":"Retrospective Multicentre Study on the Impact of Neonatal Screening for Congenital Adrenal Hyperplasia in Italy","phase":"","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07473804","title":"Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03257462","title":"Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Spruce Biosciences","has_results":true},{"nct_id":"NCT03525886","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT03669549","title":"Nevanimibe HCl for the Treatment of Classic CAH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Millendo Therapeutics US, Inc.","has_results":true},{"nct_id":"NCT03687242","title":"Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Spruce Biosciences","has_results":true},{"nct_id":"NCT03718234","title":"Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT02804178","title":"A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Millendo Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04045145","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT01859312","title":"Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":true},{"nct_id":"NCT07187375","title":"Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Neurocrine Biosciences","has_results":false},{"nct_id":"NCT03897504","title":"Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty","phase":"NA","overall_status":"UNKNOWN","enrollment_count":5,"lead_sponsor_name":"Kasr El Aini Hospital","has_results":false},{"nct_id":"NCT02574910","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT05663320","title":"A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT03532022","title":"Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Neurocrine UK Limited","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}